NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, synthetic biology company Intrexon said after the close of the market on Thursday that revenues in its third quarter more than doubled year over year.

Total revenues for the three months ended Sept. 30 reached $6.1 million, up from $2.9 million a year ago, driven by an uptick in collaboration revenues, which increased to $6.0 million from $2.9 million a year ago. Other revenues were up to $105,000 from $21,000.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.